ONCAlert | 2018 ASCO Annual Meeting

PD-1 Inhibitors for Hematologic Malignancies

Philippe Armand, MD, PhD
Published Online: 10:43 PM, Sat December 6, 2014
Philippe Armand, MD, PhD, senior physician, Dana-Farber Cancer Institute, discusses the utility of PD-1 inhibitors for hematologic malignancies.

Clinical Pearls

  • It is unknown as to whether PD-1 inhibitors could be combined with chemotherapy or immunotherapy in hematologic malignancies.
  • Nivolumab showed efficacy in classical Hodgkin lymphoma, but it was one of the first studies to analyze the class of drugs into hematologic malignancies.

<<< Go back to the ASH conference page

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.